Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 8, 2009, Pages 525-532

  Abe, M ^a   Okada, K ^a   Maruyama, T ^a   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin inhibition; Chronic kidney disease; Hydrochlorothiazide; Hypertension; Renin

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; NIFEDIPINE; PREMINENT; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG ERUPTION; EVENING DOSAGE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MICTURITION DISORDER; MORNING DOSAGE; PROTEIN URINE LEVEL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY DISEASES; LOSARTAN; MALE; MIDDLE AGED;

EID: 70249151699     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47525     Document Type: Article

References (36)

1. Brenner BM, Cooper MD, De Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001; 345: 861-869.
2. Chan JCN, Wat NMS, So WY et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: An Asian perspective from the RENAAL study. Diabetes Care. 2004; 27: 874-879.
3. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572.
4. Cusachs AR, Schmieder RE, Triposkiadis F et al. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens. 2008; 26: 813-818.
5. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003.
6. Dzau VJ. Theodore Cooper Lecture: tissue angiotesin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001; 37: 1047-1052.
7. Fujita T, Ando K, Nishimura H et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to rennin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007; 72: 1543-1549.
8. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004; 19: 2784-2788.
9. Iino Y, Hayashi M, Kawamura T et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study. Hypertens Res. 2004; 27: 21-30.
10. Imai E, Horio M, Nitta K et al. Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis. 2007; 50: 927-937.
11. Iodice C, Balletta M, Minutolo R et al. Maximal suppression of rennin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int. 2003; 63: 2214-2221.
12. Jafar TH, Stark PC, Schmid CH et al. AIPRD Study Group. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int. 2001; 60: 1131-1140.
13. Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for Management of Hypertension (JSH 2004). Hypertens Res. 2006; 29 (Suppl): S1-S105.
14. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004; 363: 2022-2031.
15. Keilani T, Danesh F, Schlueter W, Molteni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis. 1999; 33: 450-457.
16. Kimura G. Sodium, kidney and circadian rhythm of blood pressure. Clin Exp Nephrol. 2001; 5: 13-18.
17. Kurokawa K, Juliana CN, Cooper ME, Keane W, Shahinfar S, Zhang Z. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol. 2006; 10: 193-200.
18. Lavermann GD, Henning RH, De Jong PE, Navis G, Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001; 38: 1381-1384.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med. 1993; 329: 1456-1462.
20. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents-a preliminary report. Hypertension. 2007; 49: 272-275.
21. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008; 372: 547-553.
22. Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Mascio G. The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int. 2000; 57 (Suppl 75): 44-48.
23. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res. 2008; 31: 7-13.
24. National Kidney Foundation. DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S76-S110.
25. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res. 2007; 30: 325-334.
26. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983; 1: 1175-1179.
27. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-766.
28. Prisant LM. Fixed low dose combination in first-line treatment of hypertension. J Hypertens. 2002; 20: S11-S19.
29. Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia. 2005; 11: 2241-2247.
30. Russo D, Minutolo R, Pasani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001; 38: 18-25.
31. Sheinfield GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999; 12: 80-85.
32. Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis. 2006; 47: 8-14.
33. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005; 4: 6.
34. Weidmann P, Boehlen LM, Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant. 1993; 8: 582-584.
35. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens. 2006; 24: 19-27.
36. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin? AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res. 2003; 92: 322-329.